RE:RE:RE:RE:Off Label Indications - Ethan Thomas post reminder Sah... agree. The BoD established a SUB Committee a number of months ago... I think it includes Best, James, Galbraith, Clulow and Wendel. Its specific mandate is IP MONETIZATION Strategy and Action.
I have full confidence things are happening.
I had the pleasure of sitting Bruce Pritchard at the Shareholders dinner. I really like and respect him and his very matter-of-fact manner. I rest assured with him back in the CFO role that things are going to tighten up. In fact, I suspect we are going to see quite a different message on the Q3 call. I think we will get much more clarity and assurance that costs and spending are more than under control and wouldnt be surprised if there was some appropriate rationalization and focus on priorities. He GETS IT.
The ultimate irony in all of this, is with them couring Investment Banks in NY, there is almost no doubt they are being told to hang on to as much IP as possible for as long as possible..... because it will ultimately justify a much higher Nasdaq valuation. I see a scenario where they sell an entire indication rights worldwide.... or where a significant drug company takes a significant ownership share in the company overall with some options on licensing. Either way, its increasingly clear they have more good options than they have ever had to take the Balance Sheet discussion right off this board.